Attovia Therapeutics, Inc. cash flow to debt ratio of 0.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Attovia Therapeutics, Inc. has insufficient data to evaluate this check.

Attovia Therapeutics, Inc. has insufficient data to evaluate this check.

Attovia Therapeutics, Inc. has insufficient data to evaluate this check.

Attovia Therapeutics, Inc. has a net cash position, so leverage is healthy.

Attovia Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Attovia Therapeutics, Inc. has insufficient data to evaluate this check.

Attovia Therapeutics, Inc. has insufficient data to evaluate this check.

Attovia Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Attovia Therapeutics, Inc.'s return on equity of -25.47%, is lower than 15.00%, indicating bad performance

Attovia Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Attovia Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Attovia Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Attovia Therapeutics, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Attovia Therapeutics, Inc.'s yearly earnings has decreased 52.33% since last year from $-39.80M to $-60.63M, signaling decreasing performance

Attovia Therapeutics, Inc. has insufficient data to evaluate this check.

ROIC -26.08% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Attovia Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Attovia Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Attovia Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Attovia Therapeutics, Inc. has insufficient data to evaluate this check.

Attovia Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Attovia Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Attovia Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Attovia Therapeutics, Inc. has insufficient data to evaluate this check.

Attovia Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Attovia Therapeutics, Inc. has a price-to-book ratio of 5.76x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Attovia Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue